Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
about
Profile of palbociclib in the treatment of metastatic breast cancerThe role of taxanes in triple-negative breast cancer: literature reviewAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelineOptimal management of breast cancer in the elderly patient: current perspectivesRole of positron emission tomography for the monitoring of response to therapy in breast cancerMeta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapyTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.Triple-negative breast cancer: role of specific chemotherapy agentsPredictions of the pathological response to neoadjuvant chemotherapy in patients with primary breast cancer using a data mining technique.Tumor-infiltrating CD8+ and FOXP3+ lymphocytes in triple-negative breast cancer: its correlation with pathological complete response to neoadjuvant chemotherapy.The potential prognostic value of connexin 26 and 46 expression in neoadjuvant-treated breast cancerA systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancerEfficacy control of therapy using circulating epithelial tumor cells (CETC) as "liquid biopsy": trastuzumab in HER2/neu-positive breast carcinomaPrognostic role of YB-1 expression in breast cancer: a meta-analysisPrediction of Response to Neoadjuvant Chemotherapy: New Biomarker Approaches and Concepts.Effect of neoadjuvant chemotherapy in patients with triple-negative breast cancer: A meta-analysis.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialOverexpression of the EMT driver brachyury in breast carcinomas: association with poor prognosis.Association between HER2 status and response to neoadjuvant anthracycline followed by paclitaxel plus carboplatin chemotherapy without trastuzumab in breast cancer.Human epidermal growth factor receptor-2-positive breast cancer: does estrogen receptor status define two distinct subtypes?Nottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.Lateral differences in Ki-67 in breast cancerNeoadjuvant endocrine treatment for breast cancer: from bedside to bench and back again?Nottingham Prognostic Index Plus (NPI+): a modern clinical decision making tool in breast cancer.Can some patients avoid adjuvant chemotherapy for early-stage breast cancer?Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?Macroscopic handling and reporting of breast cancer specimens pre- and post-neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches.Estrogen receptor status confers a distinct pattern of response to neoadjuvant chemotherapy: implications for optimal durations of therapy: distinct patterns of response according to ER expression.Prognostic values of Ki-67 in neoadjuvant setting for breast cancer: a systematic review and meta-analysis.The predictive value of Ki-67 before neoadjuvant chemotherapy for breast cancer: a systematic review and meta-analysis.Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using (18)F-FDG PET in luminal HER2-negative breast cancer.Prognostic and predictive value of NanoString-based immune-related gene signatures in a neoadjuvant setting of triple-negative breast cancer: relationship to tumor-infiltrating lymphocytes.Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer.Differential pathological response to preoperative chemotherapy across breast cancer intrinsic subtypes.Long-term significance (15 years) of pathological complete response after dose-dense neoadjuvant chemotherapy in breast cancer.Pathological responses and long-term outcome analysis after neoadjuvant chemotheraphy in breast cancer patients from Kuwait over a period of 15 years.The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.Predictive value of sphingosine kinase 1 expression in neoadjuvant treatment of breast cancer.BIRC5 (survivin): a pejorative prognostic marker in stage II/III breast cancer with no response to neoadjuvant chemotherapy.
P2860
Q26747737-44AA6F11-FF62-450B-B5EA-644ED9FDED97Q26798356-18D4C700-49D7-4BBC-8619-453859C5DCE3Q26853619-98CEE06C-BEAC-4FDA-877B-6E7E30F726AAQ27690879-349F585F-E17A-4EC4-9F58-15CB3628A1D6Q28080621-35803742-F6A7-4AE9-959A-403922C34083Q33573055-3C75923C-D386-4D62-B124-F5A841E199F9Q33769821-8C17EA57-5B9F-4F99-9402-43A1874DB19DQ33900930-806CB35F-31DB-4022-A98A-E683910335FAQ34300562-9DF0AAAF-ECC0-4D6B-969E-99A38F1429B7Q34447829-3BB3EF59-F80A-4EC1-99C1-22CF88B65CB9Q34572215-B3A942F9-029A-4198-B08A-6F2DED719C3AQ35108403-502072C7-99BF-455A-ABF8-021F646B6EC0Q35161280-3D8281DD-2043-4FCD-BEA7-8D148BA2F22DQ35479413-76C71FCB-EFFE-4A61-9C9A-E018A6AD091BQ35576250-03DAD95C-A35A-48E0-8DE3-C73928628845Q35759050-062CC957-5A4A-49E7-8DC2-85ECE14CB999Q35889568-B0528006-34EE-4F79-B5BE-6BC733A0D477Q36057732-F30E07A4-1884-4383-91CD-981CF7B26212Q36419109-EA4CE55F-2331-42F3-AA2F-D03FB3B69572Q36551617-C5E9CB72-E7C2-4348-9CDE-15C0295C3D46Q36873822-0E1EF7DD-2259-4428-A8CF-74D44C7CB4E2Q36908377-9EBCA0A0-D80F-40ED-BAFB-72F2F9F2FC0CQ36953869-76FE4F92-723A-447B-B9BF-94F1B674CF1AQ37577665-B3B8432C-24BC-47E7-BCD2-6578E3157A19Q37681710-45AD9DAA-8B1F-4E2C-BCF6-8069E03F31BBQ37848654-B7A820DE-D242-4188-855F-FB47232D3F73Q38195674-A0080411-FCA1-425A-8343-4D330F90341EQ38317182-89276D11-DCB2-40E9-BD70-156CFF50B4FCQ38461102-D59C86E0-0279-4950-8BFA-7AA9ED7030F9Q38770344-778B52F6-2B23-42E6-8CFF-627F9B23A7A6Q38771946-DAF9F68B-AE47-4CB7-8E01-06AFF5A3776DQ39311162-3CD9DA88-45C1-4333-8A2B-7229953F0ACAQ41719270-628171EB-15F7-421A-A1A2-CA7A1501F04BQ42024318-7B41CBFB-C3AA-4FBA-8B66-941B06BAA352Q42517316-70AA3686-D0AC-4095-991D-45FFFF6D4549Q44332598-D5470617-79FB-41A6-A0B9-FD1BA25D306EQ46214920-5D7DA83E-EB15-4456-86C7-0DEBD9475CDAQ47205521-1DBB4496-FFE5-45D7-8AEA-B684553B5D5DQ47753783-56E13FB2-C6CE-45A7-932C-AC1D469B73C2Q48371625-31C5AF32-617A-4B90-82AB-34605571B626
P2860
Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Identification of biology-base ...... line/taxane-based chemotherapy
@en
Identification of biology-base ...... ine/taxane-based chemotherapy.
@nl
type
label
Identification of biology-base ...... line/taxane-based chemotherapy
@en
Identification of biology-base ...... ine/taxane-based chemotherapy.
@nl
prefLabel
Identification of biology-base ...... line/taxane-based chemotherapy
@en
Identification of biology-base ...... ine/taxane-based chemotherapy.
@nl
P2093
P2860
P50
P356
P1476
Identification of biology-base ...... line/taxane-based chemotherapy
@en
P2093
Andreas du Bois
Berit M Müller
Bernd Gerber
Carsten Denkert
Christian Jackisch
Jan Budczies
Jens Uwe Blohmer
Karsten Schlüns
Klaus Richter
Manfred Kaufmann
P2860
P2888
P356
10.1186/BCR2363
P577
2009-01-01T00:00:00Z
P5875
P6179
1021575073